September 3, 2025 — Leads & Copy — CG Oncology, Inc. (NASDAQ: CGON) has completed enrollment in its Phase 3 PIVOT-006 study. The study compares adjuvant intravesical cretostimogene grenadenorepvec versus surveillance following bladder tumor removal in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC).
According to Robert Svatek, M.D., MSCI, urologic oncologist at the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, intermediate-risk NMIBC presents a significant clinical challenge, with recurrence rates reaching up to 70% and few durable treatment options available to patients. Vijay Kasturi, MD, Chief Medical Officer at CG Oncology, said that the company remains steadfast in its mission to transform the treatment landscape for individuals living with bladder cancer.
PIVOT-006 is a Phase 3, randomized, open-label trial in intermediate-risk NMIBC comparing adjuvant intravesical cretostimogene grenadenorepvec to surveillance after bladder tumor removal. Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 400 patients with Non-Muscle Invasive Bladder Cancer (NMIBC).
Sarah Connors, Vice President, Communications and Patient Advocacy, CG Oncology, sarah.connors@cgoncology.com
Megan Knight, Vice President, Investor Relations, CG Oncology, megan.knight@cgoncology.com
Source: CG Oncology
